Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

von Hippel-Lindau Disease 1Glioblastoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × PT2385 × Clear all
NCT03108066 2024-09-24

MK-3795-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Completed
4 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03216499 2022-05-09

PT2385

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
24 enrolled 11 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡